Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.


Journal

Addictive behaviors
ISSN: 1873-6327
Titre abrégé: Addict Behav
Pays: England
ID NLM: 7603486

Informations de publication

Date de publication:
11 2019
Historique:
received: 30 01 2019
revised: 04 05 2019
accepted: 20 06 2019
pubmed: 22 7 2019
medline: 3 11 2020
entrez: 22 7 2019
Statut: ppublish

Résumé

Opioid use disorder (OUD) and opioid-related overdose mortality are major public health concerns in the United States. Recently, several community-based and professional innovations - including hybrid recovery community organizations, peer-based emergency department warm handoff programs, emergency department buprenorphine induction, and low-threshold OUD treatment programs - have emerged or expanded in an effort to address significant obstacles to providing patients the care needed for OUD and to reduce the risk of overdose. Additional innovations are needed to address the crisis. Building upon the foundational frameworks of each of these recent innovations, a new model of OUD pharmacotherapy is proposed and discussed: the Recovery Community Center Office-Based Opioid Treatment model. Additionally, two potential implementation scenarios, the overdose and non-overdose event protocols, are detailed for communities, peers, and practitioners interested in implementing the model. Potential barriers to implementation of the model include service reimbursement, licensing regulations, and organizational concerns. Future research should seek to validate the model and to identify actual implementation and sustainability barriers and best practices.

Identifiants

pubmed: 31326776
pii: S0306-4603(19)30139-X
doi: 10.1016/j.addbeh.2019.106031
pmc: PMC7286074
mid: NIHMS1591319
pii:
doi:

Substances chimiques

Narcotic Antagonists 0
Buprenorphine 40D3SCR4GZ

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

106031

Subventions

Organisme : Intramural NIH HHS
ID : ZIA DA000629
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

MMWR Morb Mortal Wkly Rep. 2012 Feb 17;61(6):101-5
pubmed: 22337174
NCHS Data Brief. 2017 Dec;(294):1-8
pubmed: 29319475
N Engl J Med. 2006 Jul 27;355(4):365-74
pubmed: 16870915
Harm Reduct J. 2018 Oct 22;15(1):52
pubmed: 30348170
JAMA. 2015 Apr 28;313(16):1636-44
pubmed: 25919527
Biol Psychiatry. 2004 Nov 15;56(10):764-70
pubmed: 15556121
J Subst Abuse Treat. 2016 Sep;68:68-73
pubmed: 27431049
Ann Intern Med. 2017 Feb 21;166(4):268-278
pubmed: 27919103
Addict Sci Clin Pract. 2017 Feb 28;12(1):7
pubmed: 28245872
Addiction. 2019 Mar;114(3):471-482
pubmed: 30194876
J Gen Intern Med. 2005 Nov;20(11):1038-41
pubmed: 16307630
Drug Alcohol Depend. 2018 Aug 1;189:62-69
pubmed: 29883870
J Gen Intern Med. 2017 Jun;32(6):660-666
pubmed: 28194688
Drug Alcohol Depend. 2016 Dec 01;169:117-127
pubmed: 27810654
Addict Behav. 2011 Jun;36(6):636-642
pubmed: 21276664
J Gen Intern Med. 2008 Sep;23(9):1393-8
pubmed: 18592319
Curr HIV/AIDS Rep. 2018 Aug;15(4):293-301
pubmed: 29968173
J Subst Abuse Treat. 2012 Apr;42(3):231-8
pubmed: 22000323
Ann Emerg Med. 2018 Oct;72(4):420-431
pubmed: 29880438
J Addict Med. 2014 Sep-Oct;8(5):299-308
pubmed: 25254667
J Addict Nurs. 2016 Apr-Jun;27(2):120-6
pubmed: 27272996
Eval Program Plann. 2011 Nov;34(4):375-81
pubmed: 21371752
Psychiatr Rehabil J. 2016 Sep;39(3):197-203
pubmed: 27183186
J Rural Health. 2019 Jan;35(1):108-112
pubmed: 29923637
J Subst Abuse Treat. 2011 Jun;40(4):349-56
pubmed: 21310583
J Addict Med. 2015 Sep-Oct;9(5):358-67
pubmed: 26406300
Addict Behav. 2011 Jun;36(6):584-589
pubmed: 21377275
Drug Alcohol Depend. 2016 Apr 1;161:1-8
pubmed: 26832931
Health Aff (Millwood). 2019 Jan;38(1):14-23
pubmed: 30615514
Drug Alcohol Depend. 2013 Nov 1;133(1):121-6
pubmed: 23773951
Eur Addict Res. 2011;17(1):44-54
pubmed: 20975276
BMC Health Serv Res. 2012 Jul 19;12:205
pubmed: 22812608
Alcohol Treat Q. 2010;28(4):391-416
pubmed: 30880870
JAMA Psychiatry. 2019 Mar 1;76(3):229-230
pubmed: 30586140
J Subst Abuse Treat. 2016 Apr;63:1-9
pubmed: 26882891
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242
pubmed: 29779547

Auteurs

Robert D Ashford (RD)

University of the Sciences, Substance Use Disorders Institute, United States of America. Electronic address: rashford@mail.usciences.edu.

Austin M Brown (AM)

Kennesaw State University, Center for Young Adult Addiction & Recovery, United States of America.

Jessica McDaniel (J)

Kennesaw State University, Center for Young Adult Addiction & Recovery, United States of America.

Jenna Neasbitt (J)

Center for Social Innovation, United States of America.

Chad Sobora (C)

Missouri Network For Opiate Reform and Recovery, United States of America.

Robert Riley (R)

Missouri Network For Opiate Reform and Recovery, United States of America.

Lesley Weinstein (L)

Missouri Network For Opiate Reform and Recovery, United States of America.

Aaron Laxton (A)

Missouri Network For Opiate Reform and Recovery, United States of America.

Justin Kunzelman (J)

Rebel Recovery, United States of America.

Kyle Kampman (K)

University of Pennsylvania, Center for Studies of Addiction, United States of America.

Brenda Curtis (B)

National Institutes of Health, National Institute on Drug Abuse, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH